1. Scrip

How 2018 Will Affect The Depression Market

 
• By Lucie Ellis-Taitt

Depression therapy has seen little advancement in the last decade but treatment-shifting events are imminent; growth in the depression market will come from sales of new drug classes, including those targeting the NMDA and opioid receptor pathways.

Maple leaves
A year of change: new therapies emerging in depression • Source: Shutterstock

There are several catalysts expected to disrupt the depression market in 2018 including regulatory filings and approvals for potential blockbuster drugs, and key data read outs for therapies to treat postpartum depression (PPD) – a condition that currently has no specifically approved antidepressant treatment.

In the coming year, Johnson & Johnson and Sage Therapeutics Inc. will file their respective depression drugs with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 
• By Sushmita Panda

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.